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Abstract
Second-generation antipsychotics (SGAs) are increasingly prescribed to treat psychiatric symptoms in pediatric
patients infected with HIV. We examined the relationship between prescribed SGAs and physical growth in a
cohort of youth with perinatally acquired HIV-1 infection. Pediatric AIDS Clinical Trials Group (PACTG),
Protocol 219C (P219C), a multicenter, longitudinal observational study of children and adolescents perinatally
exposed to HIV, was conducted from September 2000 until May 2007. The analysis included P219C participants
who were perinatally HIV-infected, 3–18 years old, prescribed first SGA for at least 1 month, and had available
baseline data prior to starting first SGA. Each participant prescribed an SGA was matched (based on gender, age,
Tanner stage, baseline body mass index [BMI] z score) with 1–3 controls without antipsychotic prescriptions. The
main outcomes were short-term (approximately 6 months) and long-term (approximately 2 years) changes in
BMI z scores from baseline. There were 236 participants in the short-term and 198 in the long-term analysis. In
linear regression models, youth with SGA prescriptions had increased BMI z scores relative to youth without
antipsychotic prescriptions, for all SGAs (short-term increase¼ 0.192, p¼ 0.003; long-term increase¼ 0.350,
p< 0.001), and for risperidone alone (short-term¼ 0.239, p¼ 0.002; long-term¼ 0.360, p¼ 0.001). Participants
receiving both protease inhibitors (PIs) and SGAs showed especially large increases. These findings suggest that
growth should be carefully monitored in youth with perinatally acquired HIV who are prescribed SGAs. Future
research should investigate the interaction between PIs and SGAs in children and adolescents with perinatally
acquired HIV infection.
Introduction
The number of children and adolescents with perinatallyacquired HIV-1 infection is growing at alarming rates
worldwide.1 It is estimated that 5%–10% of all persons living
with HIV are children, and most of them acquired HIV
through perinatal transmission (i.e., either via transplacental
transmission during pregnancy, during the delivery, or via
breast-feeding).2
In the United States and other parts of the world where
highly active antiretroviral therapy (HAART) is readily
available, HIV infection is no longer viewed as a fatal, rapidly
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progressive infection, but rather as a chronic life-limiting
disease. This has refocused treatment to addressing the need
to adhere to complex medication regimens, anticipating ad-
verse events from treatment, and maintaining the quality of
life, including the mental health of people living with HIV.3–6
Children and adolescents with perinatally acquired HIV-1
infection face multiple risks to their mental health, possibly
starting with in utero exposure to the antiretroviral (ARV)
medications taken during pregnancy.7,8 In addition, there is
the ongoing exposure of the developing brain to the slow but
progressive immune dysregulation that characterizes HIV
infection9,10 and the required ARV medications, some of
which appear to have significant central nervous system
(CNS)-related side effects (e.g., efavirenz).11
The risk of mental health problems continues through
childhood due to potential prior or current parental mental
illness and substance abuse, as well as environmental factors
that frequently co-occur within the context of HIV infection,
such as poverty, inadequate social support, and unstable
housing.12 Indeed, several studies13–19 have reported high
combined rates of psychiatric symptoms, cognitive disorders
and school problems in this population.
Second-generation antipsychotics (SGAs) are prescribed
frequently to children and adolescents,20–22 including those
who are HIV-infected, to treat psychiatric symptoms: in a
large cohort of U.S. children and adolescents with HIV, 2% of
the subjects had prescriptions for risperidone.17 This pre-
scribing trend is likely to continue following the U.S. Food
and Drug Administration’s (FDA) approval of risperidone
use for the symptomatic treatment of irritability in children
and adolescents with autism,23 for treatment of schizophrenia
in adolescents age 13 to 17 years, and for short-term treatment
of manic or mixed episodes of type I bipolar disorder in youth
age 10 to 17 years.24
A major advantage of SGAs over conventional antipsy-
chotics is their very low association with extrapyramidal
symptoms,25 however, growing evidence suggests an associ-
ation between SGA treatment and excessive weight gain.
Comprehensive reviews of randomized controlled pediatric
trials suggest that the weight gain is particularly prominent in
children and adolescents treated with olanzapine or risper-
idone, followed by quetiapine.18,26 In a recent clinical trial,27
there were significant increases in body mass index (BMI) z
scores in children and adolescents after 6 months of treatment
with olanzapine or risperidone. Bell et al.28 demonstrated an
independent relationship between BMI z score as a continu-
ous variable and multiple health risks in children and ado-
lescents (including significant relationship to systolic and
diastolic blood pressure, insulin during oral glucose tolerance
test, total cholesterol, high-density lipoprotein, triglycerides,
and alanine aminotransferase as well as rates of musculo-
skeletal pain, obstructive sleep apnea symptoms, headaches,
depression, anxiety, bullying, and acanthosis nigricans) either
in linear- or curvilinear fashion, suggesting the risks increase
across the entire range of BMI z score values, rather than in-
creasing only upon crossing a certain threshold value.
Taken together, this evidence gives rise to safety concerns
for youth with perinatally acquired HIV and comorbid psy-
chiatric disorders treated with SGAs who are already exposed
to risk factors independently affecting growth and metabolic
status and salient to HIV infection. For example, HIV infection
has been associated with growth retardation both in the de-
veloped and developing world,29,30 and treatment with pro-
tease inhibitors (PIs) has been strongly associated with marked
increases in total cholesterol levels in youth with HIV.31
The primary objective of the present study was to examine
the relationship between prescribed SGAs (as a class and in-
dividually) and changes in physical growth (as measured by
changes in BMI z scores) in a cohort of children and adoles-
cents with perinatally acquired HIV infection. We hypothe-
sized that children and adolescents with perinatally acquired
HIV infection who are treated with SGAs will experience
significantly higher increases in BMI z score than their coun-
terparts not treated with antipsychotics.
Methods
This study evaluated data from the Pediatric AIDS Clinical
Trials Group (PACTG), Protocol 219C cohort study (P219C), a
multicenter, longitudinal observational study of children and
adolescents perinatally exposed to HIV, conducted from
September 2000 until May 2007. P219C was a revision of
PACTG protocol 219, initiated in 1993 to study long-term ef-
fects of in utero exposure to antiretroviral (ARV) medications
and complications of HIV infection. P219C was approved by
local Institutional Review Boards at over 80 participating sites
in the United States and Puerto Rico. Informed consent and
assent were obtained according to local institutional guide-
lines. Upon enrollment, study nurses abstracted participants’
medical records to obtain medical and treatment histories,
including diagnoses and ARV and concomitant medications.
Follow-up visits included physical examinations, laboratory
studies, and self-reports from children and parents or care-
givers to provide updated demographic information, medical
history (including psychiatric and neurologic diagnoses), and
quality-of-life information.
Participants
Among the participants with prescriptions for SGAs, we
included those who started their first SGA between the ages of
3 and 18 years, continued that SGA for at least 1 month, and
had an available baseline visit prior to starting the first SGA.
Each participant with SGA prescriptions was then matched
with up to 3 perinatally HIV-infected controls without pre-
scriptions for any antipsychotics (i.e., neither conventional
nor SGA). The matching was based on the following criteria:
gender, birth date within 1 year, baseline Tanner stage cate-
gory (1, 2–3, or 4–5), and baseline BMI z score. Study nurses
recorded medication dates as reported by parents or older
participants or as documented in the medical records avail-
able to the study.
Procedures
Height and weight measurements were obtained every 3
months (1 month) from evaluations performed in routine
clinical care or during scheduled study visits, according to the
standardized protocol in P219C. Children had standing
heights measured to the nearest 0.1 cm using a stadiometer;
weights were taken without shoes. One height and weight
measurement was recorded at each visit. The baseline visits
for the participants with SGA prescriptions and matching
participants without antipsychotic prescriptions were re-
quired to be within 3 months of each other. For participants
with SGA prescriptions, the baseline BMI z score measure-
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ment was the latest measurement prior to the first medication
start date. The short-term follow-up measurement was the
measurement taken closest to 6 months after the baseline visit.
This measurement was required to be obtained no less than 1
month after starting antipsychotic drugs and within 1 year
after the baseline visit, and to occur while the participant was
still taking the first SGA. The long-term follow-up measure-
ment was the measurement taken closest to 2 years after the
baseline visit and between 1 year and 3 years after the baseline
visit. In contrast to the short-term follow-up measurement,
the patient was not required to still be taking the first drug at
the time of the long-term follow-up measurement. For the
controls, the baseline measurement was defined as the mea-
surement taken closest to the baseline visit for the matching
participant with SGA prescription. The short-term follow-up
measurement was the measurement taken closest to 6 months
after the baseline visit and between 1 month and 1 year after
the baseline visit. The long-term follow-up measurement was
the measurement taken closest to 2 years after the baseline
visit and between 1 year and 3 years after the baseline visit.
The outcomes of interest were short-term and long-term
change in BMI z score as measured from a baseline visit to a
follow-up visit. Height-for-age and weight-for-age z scores
were calculated with reference to national norms for U.S.
children and adolescents.32 The BMI z-score was chosen as the
primary measure of physical growth in order to adjust for the
age- and gender-appropriate developmental changes in
height and growth, as recommended in recent literature re-
views.26,33
Antipsychotic medications
The initial review of data identified children and adoles-
cents enrolled in P219C who had prescriptions for at least one
of the following SGAs: aripiprazole, quetiapine, risperidone,
olanzapine, ziprazidone, clozapine and paliperidone. We
originally intended to include conventional antipsychotics
in the analyses, defined as follows: haloperidol, loxapine,
perphenazine, thioridazine, thiothixene, chlorpromazine,
fluphenazine, pimozide, trifluoperazine, molindone, and dro-
peridol. This intent, however, was severely limited by the
small number of participants on such medications in P219C.
There were only three patients on conventional antipsychotics
that had data available for analysis of short-term change in
BMI z cores and only two patients had data for analysis of
long-term change in BMI z scores. Thus, participants with a
history of treatment with a conventional antipsychotic prior to
or concurrent with SGA therapy were excluded from the
analysis. The analysis of individual SGAs was limited to ris-
peridone alone due to the relatively small number of partici-
pants with prescriptions for individual SGAs other than
risperidone (Table 1).
Statistical methods
For each outcome of interest (short- and long-term change
in BMI z score), we used linear regression models to evaluate
the effect of any SGA versus no SGA and risperidone alone
versus no SGA, for a total of four sets of analyses. The par-
ticipant characteristics shown in Table 2 were considered as
potential covariates in the model selection process in all four
sets of analyses. In selecting a reduced model, all covariates
with p values <0.25 in either the univariate model or the full
model were considered for inclusion. These covariates were
then removed using backward elimination with a significance
level of 10%. To maintain consistency, covariates that were
significant in either of the two short-term models were in-
cluded in the final models. Similarly, the long-term final
models were adjusted for all covariates that were significant
in either of the two long-term, significant-covariate models.
Stimulant use was included in each of the four final models as
a potential confounder because of the significant imbalance in
stimulant use by SGA exposure status (Table 2) and because
of reported associations between stimulant use and weight
change (see Sirois et al.34 for example). Similarly, we con-
trolled for length of follow-up since the univariate analysis
showed some variation in follow-up time by SGA prescrip-
tion status. All of the short-term final models were adjusted
for race, stimulant use, PI use, primary caregiver (PCG), PCG
education level, and length of follow-up. The final long-term
models were adjusted for CDC class, stimulant use, PI use,
PCG, PCG education level, participation in school sports, and
length of follow-up. All analyses used data submitted to the
P219C data management center by May 2007 and were con-
ducted using SAS 9.1 software (SAS Institute Inc., Cary, NC).
Results
Among the 2589 perinatally infected participants in P219C,
119 (5%) had a history of SGA use. Of these, 45 were excluded
for the following reasons: incomplete drug history (n¼ 5),
Table 1. Frequency Distribution of the Second-Generation Antipsychotics
Prescribed to Study Participants
Short-term follow-up Long-term follow-up
First-prescribed Ever-prescribed First-prescribed Ever-prescribed
Antipsychotic n %a n %a n %a n %a
Risperidone 40 67% 41 68% 34 67% 35 69%
Olanzapine 8 13% 9 15% 6 12% 7 14%
Aripiprazole 6 10% 8 13% 5 10% 8 16%
Quetiapine 5 8% 9 15% 5 10% 9 18%
Ziprasidone 1 2% 3 5% 1 2% 2 4%
Total (n) 60 100% 51 100%
aPercentages were taken out of the total n for each respective group.
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started SGA prior to study enrollment (n¼ 34), used first SGA
for less than 1 month (n¼ 5), or was prescribed a conventional
antipsychotic medication prior to or concurrently with an
SGA (n¼ 1). The remaining 74 participants were considered
potentially eligible for inclusion in the analysis.
Short-term change in BMI z score
Of these 74 participants, 11 did not have either a baseline
measurement or a follow-up measurement within the speci-
fied time windows, 2 discontinued the first SGA before a
follow-up measurement could be taken, and 1 had a ques-
tionable baseline BMI z score value. A sensitivity analysis
determined that the impact of excluding the questionable
observation was minimal. The remaining 60 participants with
SGA prescription history had evaluable short-term growth
data that were used in the primary short-term analysis
(Table 1). The total sample size, including controls, for the pri-
mary short-term analysis was 236 (60 participants prescribed
SGAs and 176 controls). The risperidone-alone short-term
analysis is based on the 40 participants who were prescribed
risperidone and their 118 matching controls (n¼ 158).
The overall distribution of the matched characteristics was
as follows: the plurality of participants (37%) were in the 12–
15 years age category, followed by 9–12 years (27%), 6–9 years
(17%), 15–18 years (13%), 18–21 years (4%) and 3–6 years (3%);
the majority of participants were male (71%); the plurality of
participants (47%) were in the Tanner stage I at the time of
their baseline visit; baseline BMI z score values were of highest
frequency in the range 0 to 1 (35%), followed by 1 to 3 (30%),
1 to 0 (27%), and 3 to 1 (8%).
Participant baseline characteristics and the corresponding
frequency distributions (overall and by SGA prescription
status) are shown in Table 2. Of note, there was a significant
difference between participants with and without SGA pre-
scriptions with respect to the proportion who were prescribed
stimulants during the growth observation period (42% versus
14%, p< 0.001). There was also a significantly larger propor-
tion of SGA-prescribed participants with at least one recorded
neurologic (documented as: ‘‘encephalopathy=cerebral palsy,’’
‘‘hypotonia,’’ ‘‘microcephaly=failure to thrive,’’ or ‘‘epilepsy=
seizure=infantile spasm’’) or psychiatric diagnosis (docu-
mented as: ‘‘ADHD=behavior disorder,’’ ‘‘depression=anxiety=
bipolar disorder,’’ or ‘‘intellectual disabilities=developmental
disorder’’) at baseline than participants without antipsychotic
prescriptions (63% versus 32%, p< 0.001).
The average duration of short-term follow-up was 6
months (standard deviation [SD]¼ 1.3) among the partici-
pants prescribed SGAs, and 5.7 months (SD¼ 1.5) among
those not prescribed SGAs ( p¼ 0.1). The average short-term
Table 2. Baseline Characteristics of Subjects Included in the Short-Term Analysis
Characteristic
Overall
(n¼ 236)
With
prescriptions
(n¼ 60)
Without
prescriptions
(n¼ 176) p value
Race=Ethnicity 0.80a
White, non-Hispanic 26 (11%) 8 (13%) 18 (10%)
Black, non-Hispanic 136 (58%) 36 (60%) 100 (57%)
Hispanic 69 (29%) 16 (27%) 53 (30%)
Other 5 (2%) 0 (0%) 5 (3%)
CD4 Percentb 0.14c
0–<15 27 (12%) 5 (8%) 22 (13%)
15–25 62 (27%) 13 (22%) 49 (28%)
>25 144 (62%) 42 (70%) 102 (59%)
HIV RNA (copies=mL)b 0.06c
0–400 116 (50%) 35 (58%) 81 (47%)
>400–10000 66 (28%) 17 (28%) 49 (28%)
>10,000 50 (22%) 8 (13%) 42 (24%)
Primary caregiver (PCG) 0.11a
Self 1 (0%) 0 (0%) 1 (1%)
Biological parent 93 (39%) 16 (27%) 77 (44%)
Relative 53 (22%) 14 (23%) 39 (22%)
Other adult 80 (34%) 26 (43%) 54 (31%)
Shelter=home 9 (4%) 4 (7%) 5 (3%)
CDC Class Ce 60 (25%) 18 (30%) 42 (24%) 0.39d
At least one PI in ARV regimen 182 (77%) 48 (80%) 134 (76%) 0.60d
Stimulant use 49 (21%) 25 (42%) 24 (14%) < 0.001d
PCG with high school educational level 63 (27%) 16 (27%) 47 (27%) 0.76d
Recent stressful life event 100 (44%) 22 (38%) 78 (46%) 0.36d
Activities limited by health 37 (17%) 10 (18%) 27 (16%) 0.84d
Participated in sports 139 (63%) 32 (57%) 107 (65%) 0.34d
At least one neurologic or psychiatric diagnosis 94 (40%) 38 (63%) 56 (32%) <0.001d
aPearson’s w2 test.
bData is closest to and within 6 months of baseline visit.
cMantel-Haenszel w2 test.
dFisher’s exact test.
eData is closest to and before baseline visit.
PI, protease inhibitor; ARV, antiretroviral.
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change in BMI z score was 0.222 (SD¼ 0.546) among the SGA-
prescribed and 0.003 (SD¼ 0.236) among the participants
without SGA prescriptions ( p¼ 0.002). Figure 1 summarizes
the distribution of BMI z scores at baseline and follow-up
measurements, showing trends in short-term growth with
respect to prescribed SGA treatment.
In the final models (Table 3), positive short-term BMI z-
score changes were found to be independently predicted by
prescribed SGA treatment (slope¼ 0.193, p¼ 0.003) as well as
by prescribed risperidone (slope¼ 0.244, p¼ 0.002). Con-
comitantly prescribed stimulant medications were not found
to be significantly predictive of the short-term BMI z score
changes in either case. Supplemental modeling that investi-
gated potential interaction effect showed the presence of a
significant short-term interaction between SGAs and PIs
(slope¼ 0.230, p¼ 0.03), as well as between risperidone and
PIs (slope¼ 0.369, p¼ 0.01) in predicting change in BMI z
scores.
Long-term change in BMI z score
Of the 74 potentially eligible participants, 51 participants
with SGA treatment history were included in the primary
long-term analysis. The total sample size, including 147 con-
trols, for the primary long-term analysis was 198. The sample
size for the final model was 184 due to missing observations in
some of the covariates. The baseline characteristics of partic-
ipants included in the long-term change analysis (not shown)
were very similar to those in the short-term analysis, includ-
ing the significantly higher representation of participants with
SGA prescriptions who were also prescribed stimulants
( p< 0.001) and those with at least one neurologic or psychi-
atric diagnosis ( p¼ 0.001). The risperidone long-term analysis
is based on 34 patients who were first prescribed risperidone
and their 98 matching controls, for a total sample size of 132.
The sample size for the final model was 122 due to missing
observations in some of the covariates.
The average duration of the long-term follow-up was 21.9
months (SD¼ 3.6) among the participants with SGA pre-
scriptions, and 22.0 months (SD¼ 4.0) among those without
SGA prescriptions ( p¼ 0.94). The average long-term change
in BMI z score was 0.302 (SD¼ 0.668) among the participants
with SGA prescriptions, and 0.024 (SD¼ 0.302) among the
participants without SGA prescriptions ( p¼ 0.001). Figure 2
summarizes the distribution of BMI z-scores at baseline and
follow-up measurements, showing trends in long-term
growth with respect to SGA treatment.
In the final models (Table 4), positive long-term BMI z-
score changes were independently predicted by prescribed
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FIG. 1. Change in body mass index (BMI) z-scores from
baseline to short-term follow-up (approximately 6 months)
by second-generation antipsychotics (SGA) exposure (n¼
184). Labels on x-axis: Base SGA, baseline measurement in
subjects exposed to SGA; Base no SGA, baseline measure-
ment in subject unexposed to SGA; Fwp SGA, follow-up
measurement in subjects exposed to SGA; Fwp no SGA,
follow-up measurement in subjects unexposed to SGA.
Table 3. Multiple Regression of Short-Term Change
in Body Mass Index z Score on Second-Generation
Antipsychotics Adjusted for Selected
Covariates (n¼ 236)
Predictor Slope
95%
LCI
95%
UCI
p
value
Intercept 0.184 0.349 0.019 0.03
SGA history 0.193 0.064 0.321 0.003
Stimulant use 0.059 0.081 0.199 0.41
PI use 0.098 0.025 0.171 0.008
Biological parent PCG 0.056 0.137 0.026 0.18
PCG high school graduate 0.053 0.018 0.124 0.15
Length of follow-up 0.015 0.006 0.036 0.16
Note: Risperidone use was significant in the multiple regression
model of short-term change in BMI Z-score on risperidone
( p¼ 0.002), adjusted for covariates listed above; PI use and biological
parent as PCG were significant ( p¼ 0.002 and p¼ 0.003, respectively),
and PCG high school graduate and length of follow-up were
marginally significant ( p¼ 0.08 and p¼ 0.07, respectively) in this
model.
PCG, primary caregiver; SGA, second-generation antipsychotics;
PI, protease inhibitor.
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FIG. 2. Change in body mass index (BMI) z-scores from
baseline to long-term follow-up (approximately 2 years) by
second-generation antipsychotics (SGA) exposure (n¼ 236).
Labels on x-axis: Base SGA, baseline measurement in subjects
exposed to SGA; Base no SGA, baseline measurement in
subject unexposed to SGA; Fwp SGA, follow-up measure-
ment in subjects exposed to SGA; Fwp no SGA, follow-up
measurement in subjects unexposed to SGA.
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SGA treatment and by risperidone as a first-prescribed SGA.
This finding was associated with SGA class (slope¼ 0.350,
p< 0.001), and risperidone alone (slope¼ 0.360, p¼ 0.001).
Concomitantly prescribed stimulant medications were not
significantly predictive of the long-term changes in BMI z
score for either SGA or risperidone alone ( p¼ 0.22 and 0.38,
respectively). Supplementary modeling that investigated a
potential interaction effect showed the presence of a signifi-
cant interaction between SGAs and PIs (slope¼ 0.323,
p¼ 0.03) and between risperidone and PIs (slope¼ 0.577,
p¼ 0.005) in predicting change in BMI z scores.
Discussion
In this study, we evaluated the relationship between pre-
scribed SGA treatment and short- and long-term changes in
BMI z scores relative to a pretreatment baseline in children
and adolescents with perinatally acquired HIV infection from
the PACTG 219c cohort. Sociodemographic characteristics of
the cohort were representative of the US children and ado-
lescents with perinatal HIV infection. We found that pre-
scribed SGA treatment in general and risperidone specifically,
were associated with significant increase in both short- and
long-term changes in BMI z scores. The increase in the ad-
justed mean change in BMI z score (slope) of 0.192 over an
average follow-up period of approximately 6 months in
risperidone-treated participants was particularly prominent.
Since this adjusted score already accounts for confounding
factors associated with change in BMI z scores (i.e., race,
stimulant use, PI use, PCG, education level of PCG, and
length of follow-up), this finding suggests that the increase is
likely attributable to prescription of risperidone alone.
HIV disease severity indicators were equally distributed
between both groups, suggesting the findings were not sig-
nificantly confounded by the severity of physical symptoms.
Because the participants were matched on pretreatment
baseline Tanner stages and BMI z scores, the growth observed
in the SGA-prescribed group cannot be attributed to normal
development alone, suggesting excessive growth indepen-
dently associated with prescribed SGA treatment in general
and specifically with risperidone treatment. Thus, by con-
trolling for age, gender, and general health and demographic
factors, our findings add further credibility to the reports of
treatment-emergent excessive weight gain in non-HIV–
infected pediatric populations treated with risperidone or
olanzapine.20
In the clinical setting, the findings of this study should be
interpreted cautiously and within the broader context of the
child’s specific HAART regimen, their nutritional needs, and
current and evolving health status. For example, would se-
lected children with HIV who are significantly undernour-
ished, should they develop a psychiatric disorder where an
antipsychotic is indicated, actually benefit from the SGA-
associated weight gain? Furthermore, the potential for
treatment-associated adverse effects of SGAs should always be
weighed against the risks of untreated psychiatric disorders.
Realistically, there will be clinical situations where an anti-
psychotic (SGA or other) is a standard of care with no real
alternative, such as childhood schizophrenia. There will also
be situations where an SGA is indicated, and, due to limited
resources, no other alternative is available. In such situations,
clinicians should carefully proceed with prescribing the
available antipsychotic, while the child’s metabolic status is
being monitored routinely, and communication between
child psychiatrists, pediatric HIV specialist, and primary care
provider tightly integrated into the child’s clinical care. In
most other cases, however, evidence-based treatments with
greater safety records in pediatric populations should be
considered;, for example, conventional antipsychotic pimo-
zide or a2- agonist clonidine in the treatment of tic disorders,
lithium carbonate in the treatment of bipolar disorder, or
applied behavioral analysis for disruptive behaviors in chil-
dren with autism.20
Due to the low number of participants treated with con-
ventional antipsychotics, we were unable to examine the
differential association with changes in BMI z-scores between
the two classes of antipsychotics. Thus, it would be premature
to recommend preferential prescribing of the conventional
antipsychotics, especially because the latter class of antipsy-
chotics has its own safety risks, such as extrapyramidal
symptoms and hyperprolactinemia.20
The main effect of PI use was significant in all final models
(except for the long-term model for risperidone, which may be
a function of small sample size) and is consistent with the
findings in other studies.35,36 However, the presence of a sig-
nificant interaction between PI use and prescribed SGA=
risperidone that was found in investigative modeling of both
the short-term and long-term models provides some evidence
that the effect of simultaneous SGA and PI exposure on
change in BMI z score may be stronger than the sum of the
individual effects of these two classes of drugs. This enhanced
effect of the two medication classes, with known metabolic
abnormalities in pediatric populations, might be due to CYP
450 interaction between the PIs and SGAs, particularly ris-
peridone, which is metabolized primarily through the CYP
450 2D6, an enzyme blocked by the PIs indinavir and rito-
navir. Such interaction may have led to significantly increased
peripheral blood levels of, risperidone, resulting in its in-
creased impact on growth. Adult case reports also suggest
Table 4. Multiple Regression of Change
in Long-term Body Mass Index z Score
on Second-Generation Antipsychotics
Adjusted for Selected Covariates (n¼ 184)
Predictor Slope
95%
LCI
95%
UCI
p
value
Intercept 0.195 0.562 0.172 0.30
SGA history 0.350 0.166 0.533 < 0.001
CDC class C 0.079 0.037 0.195 0.18
Stimulant use 0.101 0.262 0.060 0.22
PI use 0.127 0.005 0.248 0.04
Biological parent PCG 0.124 0.243 0.006 0.04
PCG high school
graduate
0.129 0.010 0.249 0.03
Participated in sports 0.104 0.019 0.227 0.10
Length of follow-up 0.005 0.020 0.010 0.52
Note: Risperidone was significant in multiple regression model of
long-term change in BMI z score on Risperidone ( p¼ 0.001), adjusted
for covariates listed above; CDC Class C, biological parent PCG and
PCG high school graduate were significant in this model.
PCG, primary caregiver; SGA, second-generation antipsychotic;
CDC, Centers for Disease Control and Prevention; PI, protease
inhibitor; BMI, body mass index.
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that these drug-drug interactions may enhance other adverse
events and toxicities, potentially resulting in medical emer-
gencies, such as reversible coma and extrapyramidal symp-
toms.37,38 This study was not powered for effects in an
interaction model, however, and the finding warrants further
investigation, preferably in pediatric pharmacokinetic studies
of specific ARV medications and SGAs as well as the potential
for drug–drug interactions. Interestingly, the increases in BMI
z score were relatively more pronounced for risperidone alone
than for SGAs as a class. One possible explanation of this
finding is that the weight-promoting effect is specific to in-
dividual antipsychotic drugs, rather than the entire class. In-
deed, 20% of the participants with SGA prescriptions in the
short-term analysis and 22% in the long-term analysis had
prescriptions for aripiprazole or ziprazidone, which might be
weight-neutral, or for quetiapine, which has limited and
somewhat inconsistent data regarding weight gain in children
and adolescents.20,26 Furthermore, the gap between the
weight-promoting effects of risperidone versus SGAs as a
class was particularly prominent in the short-term analysis,
where the method of evaluating the change in BMI z scores
was more rigorous (in that participants were required to have
stayed on their initial SGA medication) than in the long-term
analysis. Thus, the presence of aripiprazole, ziprazidone, and
quetiapine in the analyses of SGAs as a class could have offset
the weight gain associated with risperidone and olanzapine.
Another possible explanation is that risperidone was dosed
comparably higher than the other SGAs evaluated in the
present study (either via prescribed high doses or possibly
inadvertently, via CYP 450 interaction with the PIs). We could
not evaluate the latter two possibilities because of the small
individual numbers of participants treated with SGAs other
than risperidone and because P219C did not collect dosing
information on non-ARV medications. Finally, while the
short-term length of follow-up approximately reflects the
time the patient was prescribed the first SGA, this was not
necessarily the case in the long-term analysis; thus, the
corresponding model reflects long-term impact of the first
medication regardless of how long the patient was on that
medication.
This study has several limitations. First, SGA treatment was
not randomly assigned. Thus, one could speculate, for ex-
ample, that weight gain in children on SGAs was secondarily
aggravated by behavioral factors leading to increased food
intake in psychiatrically impaired children. It seems unlikely
that this would be a plausible sole explanation for the ob-
served difference, given its magnitude, but a randomized
controlled trial would have minimized its possible con-
founding effect. Second, P219C did not measure adherence to
medications other than ARVs, so we do not know to what
extent the prescribed SGAs were actually taken (as pre-
scribed). Given the direction of the observed associations, one
might assume that, with perfect SGA adherence, the increases
in BMI z scores in SGA-exposed youth in this study would
have been even higher, not lower. Still, because of this limi-
tation, we can only attribute the observed association to the
prescription of SGAs and refrain from attributing it to actual
SGA exposure. Future studies of this type should monitor
adherence to concomitant non-ARV medications. Finally, the
study was not designed to examine the relationship between
stimulant use and weight gain as the primary goal. As a result,
our choice of cohorts did not allow for optimal study of
stimulants (both in terms of maximizing sample size as well as
choice of periods of observation). Thus, we were only able to
look at stimulant use as a potential confounder in our explo-
ration of association between SGAs and weight gain, but
cannot claim that coadministration of stimulants does not
have impact on the SGA-associated growth changes.
Conclusion
This extensive but selective review of data from the PACTG
219C long term outcomes study has demonstrated a strong
positive association between prescribed SGA treatment, par-
ticularly risperidone, and both short- and long-term changes
in BMI z scores in children and adolescents with perinatally
acquired HIV infection. Clinicians treating children with
perinatally acquired HIV infection and comorbid psychiatric
disorders requiring SGA treatment should routinely monitor
growth and metabolic parameters utilizing a careful history
and physical, standardized height and weight assessments,
and treatment-directed laboratory studies, and maintain
communication with other prescribers involved in the child’s
clinical care.
Treatment-associated adverse effects should be weighed
against the risks of untreated psychiatric disorders. When
possible, alternative evidence-based treatments should be
considered. Pharmacokinetic studies should be designed to
examine the presence of significant drug–drug interactions in
children with perinatally acquired HIV infection that are si-
multaneously treated with HAART and SGAs. This will be
particularly important as children and adolescents receive
both HAART for their primary HIV infection and other
medications for the complications seen in this difficult and
increasingly complex disease.
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